首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice.
【24h】

Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice.

机译:小鼠补体受体1型(CR1; CD35)和2型(CR2; CD21):在正常B细胞​​亚群上表达,并且在MRL / lpr小鼠自身免疫发展过程中水平降低。

获取原文
获取原文并翻译 | 示例
           

摘要

Human complement receptors type 1 (hCR1;CD35) and type 2 (hCR2;CD21) are expressed on B lymphocytes at specific stages during differentiation and activation. These receptors play critical roles in the immune response to T-dependent Ags in addition to germinal center formation. Expression of both hCR2 and hCR1 is decreased on B lymphocytes of patients with systemic lupus erythematosus (SLE). We have studied the expression of mouse CR2 and CR1 on normal populations of mouse B lymphocytes in BALB/c mice. Our results demonstrate that expression of these receptors in the normal state closely parallels that of hCR2. During bone marrow development, expression is first detected on low B220/high IgM cells, demonstrating that complement receptors appear after central tolerance mechanisms are completed. In the splenic microenvironment the highest levels of receptor expression are found on marginal zone B lymphocytes. Mouse CR2 and CR1 are also found on peritoneal B1a and B1b cells in addition to IgA+ Peyer's patch B cells. Activation of splenic B cells under Th2 conditions results in a marked decrease in receptor expression. To determine whether the patterns of receptor expression also parallel those found in human disease, we studied the MRL lpr/lpr (MRL/lpr) model of SLE. Interestingly, we found an early decrease in complement receptor expression that is progressive and first detectable before major clinical manifestations of nephritis. We hypothesize that the early decrease in complement receptor expression such as that demonstrated by MRL/lpr mice plays an important role in the pathogenesis of murine and perhaps human SLE.
机译:在分化和激活过程的特定阶段,人类补体受体1型(hCR1; CD35)和2型(hCR2; CD21)在B淋巴细胞上表达。除了生发中心的形成,这些受体在对T依赖型Ags的免疫反应中也起关键作用。系统性红斑狼疮(SLE)患者B淋巴细胞中hCR2和hCR1的表达均降低。我们已经研究了小鼠CR2和CR1在BALB / c小鼠的正常小鼠B淋巴细胞群体中的表达。我们的结果表明,这些受体在正常状态下的表达与hCR2的表达非常相似。在骨髓发育过程中,首先在低B220 /高IgM细胞上检测到表达,表明补体受体在中枢耐受机制完成后出现。在脾脏微环境中,在边缘区B淋巴细胞上发现了最高水平的受体表达。除IgA + Peyer's贴片B细胞外,还在腹膜B1a和B1b细胞上发现了小鼠CR2和CR1。在Th2条件下激活脾脏B细胞会导致受体表达显着下降。为了确定受体表达模式是否也与人类疾病中发现的模式相平行,我们研究了SLE的MRL lpr / lpr(MRL / lpr)模型。有趣的是,我们发现补体受体表达的早期下降是进行性的,并且在肾炎的主要临床表现之前首次被检测到。我们假设,补体受体表达的早期降低(如MRL / lpr小鼠所证实的)在鼠类甚至人类SLE的发病机理中起着重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号